Recently, the development of selective androgen receptor modulators, the great effect of AR–related therapy in prostate cancer and the in-depth study of luminal androgen receptor (LAR) subtype of breast cancer have highlighted AR. This evidence concerns the gene AR and Familial prostate cancer.